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The invention relates to mutant nuclear hormone receptors 
that encode mutant nuclear hormone receptors, in which 
particular amino acid residues are substituted with respect to 
wild type, so as to be able to detect ligand binding to the 
mutant receptor by either a change in a physical property of 
the mutant receptor and/or an transcriptional induction of a 
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MUTANTS AND ASSAY SYSTEM TO 
IDENTIFY USP/RXR LIGANDS 
This speci?cation claims the bene?t of and incorporates 
by reference US. Provisional Patent Application 60/428,282 
?led Nov. 22, 2002. Additionally, all references and publi 
cations referred to herein are incorporated by reference for 
their entirety, including Xu et al. (2002) Eur. J. Biochem., 
269:6026-6036. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the ?elds of drug discovery and 
pest control. Speci?cally it provides biochemical tools and 
assays that enable the user to identify to chemical com 
pounds that are effective in activating or blocking particular 
hormone-dependent regulatory pathWays in various organ 
isms. 
2. Background 
Nuclear hormone receptors are a primary transduction 
mechanism through Which extracellular hormonal signals 
are transduced into genetic regulation of metabolic pathWays 
and developmental programs. The past tWo decades have 
seen the steady identi?cation of mammalian receptors of 
Well-knoWn ligands such as steroids, thyroid hormone, all 
trans retinoic acid (RA) as Well as the identi?cation of 
endogenous ligands for initially orphaned receptors. Simi 
larly, steroid nuclear receptors in invertebrate models of 
transcriptional regulation, such as the Drosophila melano 
gasler ecdysteroid receptor (dEcR), Were isolated a decade 
ago and used to develop important concepts in cellular 
hormonal signaling. 
In parallel to the search for receptors that can be activated 
by knoWn ligands, has been the search for ligands of orphan 
receptors of the steroid nuclear receptor superfamily, Whose 
natural ligands are unknown. The biological relevance of 
identi?cation of agonistic or antagonistic ligands for orphan 
receptors is several fold. First, the ability of a chemical 
structure to ?t into the ligand-binding pocket of an orphan 
receptor and thereby transcriptionally activate the orphan 
receptor, Would raise the possibility that the orphan receptor 
ligand-binding pocket has a conformation enabling it to bind 
With and be activated by a natural ligand of complementary 
structure. Second, the identi?cation of ligands that activate 
or antagonize an orphan receptor Would aid the discovery of 
regulatory pathWays in Which the receptor participates. 
Finally, transcriptional agonists and antagonists of orphan 
receptors provide leads to pharmacologically or agri-chemi 
cally signi?cant structures that, through the orphan receptor, 
can selectively intercede in disease pathWays or insect 
speci?c hormonal regulation. 
In an effort to reduce the exposure of humans and other 
non-target organisms to the toxic effects of pesticides, major 
commercial efforts are being made to identify chemicals that 
selectively disrupt the hormonal processes that are speci?c 
to insects (e.g., humans do not have an exoskeleton that is 
periodically shed, nor do humans go through metamorpho 
sis, as insects do). TWo particular hormonal targets for these 
commercial efforts are the insect hormones that drive molt 
ing and metamorphosis: ecdysone and juvenile hormone. 
Some commercial compounds mimicking these hormones 
have already been developed, hoWever, the concern remains 
that compounds interfering With insect hormonal signaling 
may cross-react With mammalian hormone receptors. For 
example, a metabolite of the juvenile hormone mimic 
methoprene, binds the human RXR receptor, see Dhadialla 
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et al., Annual RevieW of Entomology, 43:545-569 (1998); 
Harmon et al. Proc Natl. Acad. Sci. USA., 92:6157-6160 
(1 995). 
Identi?cation of chemical compounds that bind to the 
ligand-binding pocket of ultraspiracle, the Drosophila RXR 
ortholog, has been stymied in part by di?iculty in demon 
strating speci?c binding of a test compound to the puri?ed 
receptor. Speci?cally, it has been di?icult to demonstrate 
ligand binding because there has been no ef?cient assay for 
detecting the conformational changes in a receptor upon 
interaction betWeen a ligand and a USP and RXR. Indeed, 
the current paradigm expressed in most published models 
for USP function is that USP does not bind to any ligand in 
exerting its regulatory functions. Lezzi et al., (1999) 
Archives of Insect Biochemistry and Physiology, 41:99-106. 
A demonstration that endogenous USP can become activated 
upon binding to an agonist Would have major implications 
for the current paradigms of hormone action in invertebrates. 
Jones et al., Proc Natl. Acad. Sci. USA., 94:13499-13503 
(1 997). 
The orthology betWeen invertebrate USP and vertebrate 
RXR indicates that the USP ligand-binding pocket may be 
arranged so as to be susceptible to binding and activation by 
a terpenoid-related ligand. In a previous report, it Was 
observed that the application of methyl epoxyfarnesoate to 
cells activated a transfected reporter construct containing 
direct repeat elements to Which recombinant USP bound in 
gel shift assay. HoWever, these indirect experiments did not 
address Whether methyl epoxyfarnesoate actually binds to 
the ligand-binding pocket of the receptor, nor Whether 
endogenous USP in the transfected cells actually binds to the 
direct repeat elements, nor do they address Whether methyl 
epoxyfarnesoate-activation of the reporter is dependent 
upon liganded USP, all of Which are crucial underpinnings 
to the concept of the USP ligand-binding pocket as a viable 
target for experimental or practical agonistic or antagonistic 
ligands. 
SUMMARY OF THE INVENTION 
The invention relates to mutant nuclear hormone recep 
tors that have either altered ?uorescence properties and/or 
dominant negative activity. 
One aspect of the invention relates to nucleic acids that 
encode mutant nuclear hormone receptors, in Which particu 
lar amino acid residues are substituted With respect to Wild 
type, so as to be able to detect ligand binding to the mutant 
receptor by either a change in a physical property of the 
mutant receptor and/or an transcriptional induction of a 
nuclear hormone receptor construct. 
One embodiment of this aspect of the invention relates to 
an isolated nucleic acid capable of hybridizing to SEQ ID 
NO: 1 under stringent conditions and encoding a protein 
having a tryptophan residue in a ?rst position corresponding 
to position 477 of SEQ ID NO: 2 and a tryptophan residue 
in a second position corresponding to position 479 of SEQ 
ID NO: 2, Which upon binding an epoxy farnesoid-like 
ligand results in transcriptional activation of a nuclear 
hormone receptor reporter construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a tryptophan residue in a ?rst position 
corresponding to position 477 of SEQ ID NO: 2, Which upon 
binding an epoxy farnesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
US 7,259,254 B2 
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Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a tryptophan residue in a ?rst position 
corresponding to position 479 of SEQ ID NO: 2, Which upon 
binding an epoxy famesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a tryptophan residue in a ?rst position 
corresponding to position 302 of SEQ ID NO: 2, Which upon 
binding an epoxy famesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a tryptophan residue in a ?rst position 
corresponding to position 315 of SEQ ID NO: 2, Which upon 
binding an epoxy famesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a phenylalanine residue in a ?rst position 
corresponding to position 318 of SEQ ID NO: 2, Which upon 
binding an epoxy famesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a phenylalanine residue in a ?rst position 
corresponding to position 328 of SEQ ID NO: 2, Which upon 
binding an epoxy famesoid-like ligand results in transcrip 
tional activation of a nuclear hormone receptor reporter 
construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having a phenylalanine residue in a ?rst position 
corresponding to position 318 of SEQ ID NO: 2, and a 
phenylalanine residue in a second position corresponding to 
position 328 of SEQ ID NO: 2, Which upon binding an 
epoxy famesoid-like ligand results in transcriptional activa 
tion of a nuclear hormone receptor reporter construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an tryptophan residue in a ?rst position 
corresponding to position 498 of SEQ ID NO: 2, a tryp 
tophan residue in a second position corresponding to posi 
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a 
third position corresponding to position 318 of SEQ ID NO: 
2, Which upon binding an epoxy farnesoid-like ligand results 
in transcriptional activation of a nuclear hormone receptor 
reporter construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an tryptophan residue in a ?rst position 
corresponding to position 498 of SEQ ID NO: 2, a tryp 
tophan residue in a second position corresponding to posi 
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a 
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third position corresponding to position 328 of SEQ ID NO: 
2, Which upon binding an epoxy farnesoid-like ligand results 
in transcriptional activation of a nuclear hormone receptor 
reporter construct. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an tryptophan residue in a ?rst position 
corresponding to position 498 of SEQ ID NO: 2, a tryp 
tophan residue in a second position corresponding to posi 
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a 
third position corresponding to position 318 of SEQ ID NO: 
2, and phenylalanine residue in a fourth position correspond 
ing to position 328 of SEQ ID NO: 2, Which upon binding 
an epoxy farnesoid-like ligand results in transcriptional 
activation of a nuclear hormone receptor reporter construct. 
Another aspect of the invention relates to a nucleic acids 
that encode dominant negative mutant nuclear hormone 
receptors. 
One embodiment of this aspect of the invention relates to 
an isolated nucleic acid capable of hybridizing to SEQ ID 
NO: 1 under stringent conditions and encoding a protein 
having an phenylalanine residue in a ?rst position corre 
sponding to position 318 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
One embodiment of this aspect of the invention relates to 
an isolated nucleic acid capable of hybridizing to SEQ ID 
NO: 1 under stringent conditions and encoding a protein 
having a phenylalanine residue in a ?rst position corre 
sponding to position 318 of SEQ ID NO: 2, and a pheny 
lalanine residue in a second position corresponding to posi 
tion 328 of SEQ ID NO: 2, Which is a dominant negative 
nuclear hormone receptor. 
One embodiment of this aspect of the invention relates to 
an isolated nucleic acid capable of hybridizing to SEQ ID 
NO: 1 under stringent conditions and encoding a protein 
having an tryptophan residue in a ?rst position correspond 
ing to position 498 of SEQ ID NO: 2, a tryptophan residue 
in a second position corresponding to position 499 of SEQ 
ID NO: 2, and phenylalanine residue in a third position 
corresponding to position 318 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
One embodiment of this aspect of the invention relates to 
an isolated nucleic acid capable of hybridizing to SEQ ID 
NO: 1 under stringent conditions and encoding a protein 
having an tryptophan residue in a ?rst position correspond 
ing to position 498 of SEQ ID NO: 2, a tryptophan residue 
in a second position corresponding to position 499 of SEQ 
ID NO: 2, and phenylalanine residue in a third position 
corresponding to position 318 of SEQ ID NO: 2, and 
phenylalanine residue in a fourth position corresponding to 
position 328 of SEQ ID NO: 2, Which is a dominant negative 
nuclear hormone receptor. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an alanine residue in a ?rst position corre 
sponding to position 472 of SEQ ID NO: 2 and leucine 
residue in a second position corresponding to position 475 of 
SEQ ID NO: 2, Which is a dominant negative nuclear 
hormone receptor. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an arginine residue in a ?rst position corre 
sponding to position 302 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
US 7,259,254 B2 
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Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an arginine residue in a ?rst position corre 
sponding to position 293 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an alanine residue in a ?rst position corre 
sponding to position 288 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an alanine residue in a ?rst position corre 
sponding to position 366 of SEQ ID NO: 2, Which is a 
dominant negative nuclear hormone receptor. 
Another embodiment of this aspect of the invention 
relates to an isolated nucleic acid capable of hybridizing to 
SEQ ID NO: 1 under stringent conditions and encoding a 
protein having an alanine residue in a ?rst position corre 
sponding to position 366 of SEQ ID NO: 2 and an alanine 
residue in a second position corresponding to position 288 of 
SEQ ID NO: 2 Which is a dominant negative nuclear 
hormone receptor. 
Another aspect of the invention relates to a method 
identifying ligands of nuclear hormone receptors compris 
ing: contacting a mutant nuclear hormone receptor protein 
With a candidate ligand; and determining Whether there is a 
change in a physical property of the protein or a change in 
the transcriptional activity of the protein. 
In one embodiment of this aspect of the invention, the 
protein is a mutant USP receptor. In another embodiment, 
the protein is a mutant RXR receptor. In yet a further the 
embodiment, the ligand causes a change in the ?uorescence 
properties and/or transcriptional activity the mutant USP 
receptor mutant nuclear hormone but not in the mutant RXR 
receptor. 
Another aspect of the invention relates to a nuclear 
hormone receptor response element denoted by the formula 
YDRX comprising a direct repeat (DR) comprising tWo half 
sites separated by X nucleic acid bases; Wherein a forWard 
DR sequence is 5'-AGGTCA(N)xAGGTCA-3' (SEQ ID 
NO: 8) and a reverse DR sequence is 5'-TGACCT(N),C 
TGACCT-3' (SEQ ID NO: 9); Wherein the element com 
prises at least one DR oriented in either a forWard or reverse 
orientation; Wherein Y equals 1 to 8 forWard and/or reverse 
direct repeats; and X equals 1 to about 12. 
Another aspect of the invention relates to nuclear hor 
mone receptor reporter construct comprising a nuclear hor 
mone receptor response element, a promoter and a reporter 
nucleic acid sequence operably linked to one another; 
Wherein the hormone receptor response element denoted by 
the formula YDRX comprises a direct repeat (DR) compris 
ing tWo half sites separated by X nucleic acid bases; Wherein 
a forWard DR sequence is 5'-AGGTCA(N)xAGGTCA-3' 
(SEQ ID NO: 8) and a reverse DR sequence is 5'-TGACCT 
(N)xTGACCT-3' (SEQ ID NO: 9); Wherein the element 
comprises at least one DR oriented in either a forWard or 
reverse orientation; Wherein Y equals 1 to 8 forWard and/or 
reverse direct repeats; and X equals 1 to about 12; and 
Wherein the promoter is selected from the group consisting 
of JHE, BJHSP l, Aryl, BJHSP2, and AJHSPl. 
Additional advantages of the present invention Will 
become readily apparent to those skilled in this art from the 
folloWing detailed description, Wherein only the preferred 
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6 
embodiment of the invention is shoWn and described, simply 
by Way of illustration of the best mode contemplated of 
carrying out the invention. As Will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modi?cations in various obvi 
ous respects, all Without departing from the invention. The 
present invention may be practiced Without some or all of 
these speci?c details. In other instances, Well knoWn process 
operations have not been described in detail, in order not to 
unnecessarily obscure the present invention. Accordingly, 
the draWings and description are to be regarded as illustra 
tive in nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Activation of transfected Core promoter reporter 
through DRl2 nuclear hormone response element. (A) The 
sequences of single copies of DRl (SEQ ID NO:l3), DR4 
(SEQ ID NO:14), DR12 (SEQ ID NO:15) and mutant DR12 
(SEQ ID NO:23) enhancer elements, i.e. motifs, used in the 
nuclear hormone receptor response reporter constructs. Each 
half site is dashed underlined. Mutated residues are shoWn 
in loWer case letters. (B) On the left are the designs of the 
vector construct encoding the luciferase reporter enzyme, of 
the vector construct containing the Core promoter reporter, 
and of the three vector constructs in Which the Core pro 
moter is preceded by four tandem copies either a DRl-, a 
DR4- or a DRl2-based enhancer, With the orientation of 
each motif shoWn by the small arroWs. On the right are the 
activations of the indicated nuclear hormone receptor 
response reporter construct in response to treatment of 
transfected cells With 75 um methyl epoxyfamesoate. 
FIG. 2. Functional analysis of the DRl2 motif. (A) Gel 
mobility shift assay, using Sf9 nuclear extracts, of the same 
single DRl2 motif that Was used as an enhancer in the cell 
transfection assay in (B). The shifted probe band Was 
competitively displaced by l00>< of the unlabelled DRl2 
motif (self), but Was not competed With either by the same 
mutant DRl2 motif as failed to act as an enhancer in cell 
transfection assay in B (mutDRl2) or by the negative 
control polylinker sequence (nonself). (B) Activations of the 
indicated promoter reporter constructs in response to treat 
ment of transfected cells With 75 um methyl epoxyfame 
soate. (C) Intracellular USP binds to DRl2 hormone 
response element. Gel mobility shift assay using Sf9 nuclear 
extracts (NE) and a 32P-labelled probe that is the four 
tandem DRl2 motifs (‘4DRl2’) shoWn in FIG. 1, performed 
as described in Jones et al. (2001) Insect Biochem. Mol. 
Biol. 32, 33-49. The USP in the Sf9 nuclear extract that is 
the major binding complex (small arroW) is displaced by the 
ABll monoclonal antibody, just as We have previously 
shoWn is the effect of this antibody on recombinant dUSP 
binding to a DRl2 probe Jones et al. (2001) Insect Biochem. 
Mol. Biol. 32, 33-49. The lack of similar effect by mono 
clonal antibody against the negative control nerve transcrip 
tion factor (Elav) shoWs the speci?city of the ABll result. 
FIG. 3. Comparision of dUSP and hRXR ligand binding 
domains. (A) Selected contacts made betWeen 9-cis RA and 
residues in the hRXRO. ligand-binding pocket as determined 
from cocrystals (4.2 A or less, from Egea et al. (2000) 
EMBO J. 19, 2592-2601). On the left is also shoWn a 
conformation of epoxyfamesoic acid, exhibiting similarities 
betWeen its structure and that of the terpenoid backbone and 
carboxyl group of 9-cis retinoic acid. (B and C) RASMOL 
generated ribbon diagrams for the ligand-binding domains 
of the hRXRO. and dUSP, respectively. (B) This shoWs in the 
hRXRO. ligand-binding pocket the structure of the ligand 
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9-cis retinoic acid. (C) This shows methyl epoxyfarnesoic 
acid lain manually in the dUSP ligand-binding pocket With 
the carboxy and distal (epoxy) ends, respectively, situated in 
similar regions of the pocket as the carboxyl end and distal 
end of 9-cis RA in hRXRot. (D) An overlay of the dUSP and 
hRXR ribbon diagrams of B and C, With emphasis (White 
arroWs) on the similar placement of Gln275, Trp305, 
Leu326, Cys432 and His435 in hRXR as compared to 
Gln288, Trp318, Leu367, Cys472 and His475 in dUSP. 
FIG. 4. Dominant negative activity of USP ligand-binding 
pocket mutants. (A) Histogram (shaded boxes) shoWs the 
dominant negative effect of transfected dUSP mutant and the 
double mutant (C472A/H475L) on methyl epoxyfarnesoate 
activation of4DR12Core reporter promoters, Whereas trans 
fected Wild-type dUSP shoWs no such suppression of methyl 
epoxyfarnesoate activation, in comparison With transfection 
of Core reporter vector (reporter and expression plasmids 
transfected at 1:1 ratio). Transfection of neither the Wild 
type USP nor either mutant had any effect on the minimal 
basal activation of the Core promoter in the absence of the 
DR12 motif (clear boxes). Immunoblot of transfected cel 
lular extracts With anti-(ot-actin) and anti-dUSP (AB11) 
mAbs veri?ed that the overexpression of mutant and Wild 
type dUSP did not affect the level of expression of endog 
enous USP, and that the transfected mutant and transfected 
Wild-type dUSP Were expressed at similar levels to each 
other. The molecular Weights of the transfected and endog 
enous USPs detected by immunoblotting Were about equal 
to 50 and 52 kDa, respectively, as estimated by molecular 
siZe standards run in parallel lanes (not shoWn). (B) Pro 
gressive increase in ratio of transfected dominant negative 
plasmid DNA relative to 4DRl2Core reporter plasmid DNA 
yielded an increasing dominant negative suppression of 
methyl epoxyfarnesoate activation of reporter plasmid. 
Immunoblot veri?es that the progressively higher overex 
pression of the mutant dUSP (C472A/H475L) did not affect 
the level of expression of endogenous USP. Inset above 
shoWs calculation of transcriptional activation ratio of 
reporter promoter activity in methyl epoxyfarnesoate-treated 
cells relative to EtOH treated cells, as a function of the ratio 
of the amount of transfected mutant dUSP plasmid relative 
to amount of transfected reporter plasmid. (C) Transfection 
of plasmid expressing Wild-type USP rescues the dominant 
negative-suppression of methyl epoxyfamesoate-activation 
of the reporter promoter. Open circle, methyl epoxyfarne 
soate activation of 4DRl2Core in the absence of USP 
expressing plasmid. Hashed circle, methyl epoxyfarnesoate 
activation is suppressed by transfection With the C472A/ 
H475L dominant negative mutant. Filled circles, methyl 
epoxyfarnesoate activation is progressively restored by 
increasing doses of plasmid expressing Wild-type dUSP. In 
A-C, hormone-treated cells received 75 pm of methyl 
epoxyfarnesoate. 
FIG. 5. Bacterially overexpressed double mutant dUSP 
(C472A/H475L) and Wild-type dUSP analyZed for binding 
to DNA or to ligand. (A) The Wild-type dUSP and the 
C472AH475L mutant both similarly bound in part as a 
homodimer (upper band) and in part as a monomer (loWer 
band) to a 4DRl2 motif probe (identi?cation of monomer 
and homodimer bands Was made by comparative analysis of 
binding by other dimer-enriched vs. monomer-enriched 
fractions obtained from Superdex 200 chromatography, not 
shoWn). Control competitions With self and nonself unla 
belled excess probes con?rmed the speci?city of binding. 
The similar formation of the homodimer form by the Wild 
type USP and mutant USP, along With the similar binding to 
DNA of the Wild-type USP and mutant USP, con?rm that the 
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mutation to the ligand-binding pocket in C475A/H475L did 
not generally disrupt the structure of the receptor. (B) The 
homodimer-enriched fraction of each receptor preparation 
Was then analyZed for binding to 75 um methyl epoxyfar 
nesoate, using an intrinsic ?uorescence assay method that 
tracks ligand binding (by suppression in receptor ?uores 
cence) Jones et al., (2000) Insect Biochem. Mol. Biol. 30, 
671-679; Jones et al. (2001), Insect Biochem. Mol. Biol. 32, 
33-49. The Wild-type dUSP exhibited binding to methyl 
epoxyfarnesoate in this assay. HoWever, the double mutant 
dUSP exhibited no binding activity. ArroWs shoW time of 
addition of methyl epoxyfarnesoate or EtOH carrier. 
FIG. 6. Fluorescence response of Wild-type and P498W/ 
P499W mutant USP to farnesoid ligands. (A) The location of 
the mutational placement of the tWo tryptophan residues at 
the end of ot-helix 12. USP also possesses tWo natural 
tryptophan residues on helix 5 (W318, shoWn extending into 
pocket; W328, not shoWn, extending out of pocket). (B) 
Methyl epoxyfarnesoate binding to Wild-type USP results in 
suppression of receptor ?uorescence, While famesol and 
ethanol carrier do not have that effect. (C) Methyl epoxy 
farnesoate binding to P498W/P499W mutant results in a 
very different pattern of ?uorescence response than Wild 
type USP in B, evidencing that ot-helix 12 moves in its 
relative location upon USP binding of methyl epoxyfame 
soate. The Wild-type USP and P498W/P499W similarly 
bound in part as monomer and in part as dimer to a DR12 
probe in gel shift assay, evidencing that the P498W/P499W 
mutations did not affect receptor structure globally (not 
shoWn). 
DETAILED DESCRIPTION OF THE 
INVENTION 
Before describing the invention in greater detail the 
folloWing de?nitions are set forth to illustrate and de?ne the 
meaning and scope of the terms used to describe the inven 
tion herein: 
As used herein, “Wild type” refers to the nucleic acid or 
amino acid sequence of a particular protein as it most 
commonly occurs in nature as a normal functional protein. 
Nonetheless, it is elementary to one of skill in the art that 
such functional proteins have allelic variations. An allele is 
one of several alternate forms of a gene that can have the 
same locus on homologous chromosomes and are respon 
sible for alternative traits. Some alleles are dominant over 
others. Such normal variation are encompassed Within this 
term. Preferably, the Wild type USP nucleic acid sequence is 
provided in SEQ ID NO: 1 and the Wild type amino acid 
sequence is provided in SEQ ID NO: 2. 
“Ligands” as de?ned herein are those compounds likely 
agonists or antagonists in the activation RXR and/or USP. 
Nuclear receptors are a family of proteins involved in key 
metabolic processes With great potential as targets for the 
treatment of signi?cant diseases such as cancer, coronary 
heart disease through the regulation of serum cholesterol and 
diabetes. The nuclear receptor family contains a large group 
of transcription factors, With 49 members presently identi 
?ed in the human genome. Many members of this family 
remain incompletely understood, both in terms of physi 
ological role and activating ligands, but there is a high 
probability that these “orphan receptors” are good targets for 
drug development. As such, ligands may act as drug leads in 
the treatment of diseases Where nuclear hormone receptors 
are thought to play a role such as in the. For example, a 
nuclear receptor LXR forms RXR/LXR to induce ABC1 
reverse transporter of cholesterol to pump out cellular cho 
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lesterol, resulting in lowering dietary cholesterol. Still 
another nuclear receptor FXR forms RXR/FXR to induce 
cytochrome P450 hydroxylase CYP7A1 that metaboliZes 
cholesterol to bile acid to again loWer cholesterol level. 
Small molecular ligands that speci?cally bind to each 
nuclear receptor are novel drugs against hyperlipidemia. 
Ligands identi?ed using the compositions and methods 
disclosed herein may be useful in the activation or inhibition 
of signal transduction mediated by USP, RXR or other 
nuclear hormone receptors. These ligands are mostly ana 
logs of RXR compounds that bind to and activate RXR. 
Alternatively, the compositions and methods disclosed 
herein provide the ability to identify ligands useful in pest 
control that antagoniZe USP signaling While not cross 
reacting With mammalian RXR signal transduction. Prefer 
ably, such compounds are terpenoid-related compounds. 
More preferably, ligands are structurally related to juvenile 
hormone III, retinoic acid, or epoxy famesoid-like com 
pounds. 
“Activation” refers to the homo- or heterodimeriZation of 
nuclear hormone receptors to With their natural partners 
upon ligand binding to form a complex that is capable of 
binding a nuclear hormone receptor response element and 
inducing transcription of a gene operably linked thereto. 
“Transcriptional activity” of a protein or nuclear hormone 
receptor as used herein refers to the ability of a nuclear 
hormone receptor to homo- or heterodimeriZe, bind a 
nuclear hormone receptor response element and induce the 
transcription of any nucleic acid operably linked thereto. 
As used herein “RXR” refers to the retinoid X receptor 
(RXR) Which is a member of the nuclear hormone receptor 
family of proteins. Such receptors are also transcription 
factors, binding hormone ligands and acting together With 
others in the superfamily to activate transcripts of hormone 
responsive genes. RXR plays a uniquely important role in 
di?ferentiation, development, and homeostasis through its 
ability to serve as a heterodimeric partner to many other 
nuclear receptors. RXR is a ligand-dependent transcription 
factor. RXR is able to in?uence the activity of its partner 
receptors through the action of the ligand 9-cis retinoic acid. 
RXR contains tWo signature domains of nuclear receptor 
family proteins, i.e. DNA-binding domain and ligand bind 
ing domain (LBD). The endogenous ligand for RXR is 9-cis 
retinoic acid. RXR plays an important role in many funda 
mental biological process such as reproduction, cellular 
di?ferentiation, bone development, hematopoesis and pattern 
formation during embryogenesis. RXR is also implicated in 
some pathological conditions as neoplastic formation and it 
is a potential target for cancer therapy. 
As used herein, “USP” refers the Drosophila melano 
gasler protein Ultraspiracle. USP is a promiscuous factor, 
meaning it can dimeriZe With multiple partners. It is homolo 
gous to the vertebrate retinoid-X receptor, Which demon 
strates the ancient lineage of the nuclear receptor superfam 
ily. Partnering the Ecdysone receptor for the molting 
hormone in insects, USP activates genes involved in molt 
ing. Another target is the larval serum protein-2 gene Whose 
product accumulates in the fat body tissue. This implicates 
USP in the functioning of the fat body in larval ?ies 
(AntonieWski, 1994). The fat body serves as an energy store 
for high levels of activity and for reproduction. In contrast 
to RXR, prior to this disclosure, USP Was not not knoWn to 
have knoWn high-a?inity ligand and Was thought to be a 
silent component in the heterodimeric complex With partner 
receptors such as the ecdysone receptor. 
As used herein “mutant nuclear hormone receptors” as 
used herein refers to protein having speci?c amino acid 
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substitutions With respect to Wild type nuclear hormone 
receptors. In one embodiment, these mutations comprise 
amino acid substitutions that serve to give make changes in 
protein con?rmation due to interaction With a putative 
ligand, more easily detectable by providing the protein With 
altered ?uorescent properties. More preferably, amino acid 
substitutions are made in the ligand biding domain of the 
nuclear hormone receptors. Even more preferably, amino 
acids substitutions are made in the ligand binding domain of 
USP or RXR. 
Whereas, ligand binding does not su?iciently modulate 
the ?uorescence of Wild type receptors to facilitate ligand 
binding detection, some of the mutant receptors disclosed 
herein have markedly different ?uorescent pro?les upon 
binding a ligand. The change in ?uorescence of a mutant 
receptor upon ligand binding can be detected by such 
exemplary techniques as anisotropy, Fluorescence Reso 
nance Energy Transfer (FRET), or circular dichroism. Pref 
erably, changes in ?uorescence emission (either the magni 
tude of emission or the blue-red shift in emission) of 
tryptophan residues in the mutant receptor are monitored, in 
order to detect binding to the ligand binding pocket of the 
test mutant receptor by chemical compounds that do not 
themselves signi?cantly absorb the ?uorescent light emitted 
by the receptor. Alternatively, changes in the anisotropy 
(rotational volume) of the mutant receptor are monitored in 
order to detect binding of chemical compounds to the ligand 
pocket Whose e?fects on the receptor are to either promoter 
or inhibit the binding of tWo identical mutant molecules into 
a dimer pair, i.e., formation of “homodimer”. 
In another embodiment, mutant nuclear hormone recep 
tors disclosed herein comprise amino acid substitutions that 
render the mutant to act as a “dominant negative.” Dominant 
negative proteins exploit protein-protein interactions, i.e., 
the interactions betWeen a mutated protein produced by a 
transgene and the related native protein inside the cell. The 
mutant protein forms a dimer With an integral part of a Wild 
type endogenous protein molecule. The mutant protein inter 
acts With a Whole range of native compatible gene products. 
Preferably, the mutant homodimeriZes or heterodimeriZes 
With an endogenous Wild type partner to form a complex 
folloWing ligand or independent of ligand binding. Prefer 
ably, as opposed to a complex of Wild type monomers, a 
complex of a mutant and its endogenous Wild type partner 
Will be incapable of initiating transcription at a hormone 
receptor response reporter gene. Assays for determining 
dominant negative activity may be found in Examples 6 and 
7 as Well as FIG. 4. 
In yet another embodiment, mutant nuclear hormone 
receptors have both altered ?uorescent properties upon 
ligand binding as Well as dominant negative activity. For 
example, USP W318F is a Weak dominant negative that by 
the elimination of the ?uorescence emitting tryptophan from 
W318 also enables more sensitive tracking of the tracking of 
changes in ?uorescence emitted by W328. W328F is not a 
dominant negative. HoWever, elimination of the ?uores 
cence emitting tryptophan from W328 enables more sensi 
tive tracking of the in ?uorescence emitted by W318. 
P498W/P499W is not a dominant negative, but is used to 
detect the movement of alpha helix 12. HoWever, the 
P498W/P499W is not the most e?icient ?uorescent detector 
of movement of alpha helix 12 because of the additional 
?uorescence being contributed by the Wild type residues 
W318 and W328. So, When either W318, W328 or both are 
mutated aWay as W318F and/or W328F, removal of their 
contributing “background” ?uorescence enables the ?uores 
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cent signaling from P498W/P499W to be more sensitive, 
indicating movement of alpha helix 12. 
A list of some of the mutants envisioned by the invention 
is summarized in Table 1 beloW: 
Altered Fluorescence 
With Respect 
to Wild Type 
Dominant 
USP Mutant Negative Activity 
Weak Activity 
Weak Activity 
Weak Activity ++++++++++++ Weak Activity 
lllll +++++++ 
Amino acid residue positions “corresponding” to one 
another as used herein, refers to the fact that there are 
conserved amino acid residues among orthologous proteins 
or among structurally similar mutant receptors that are 
encoded by substantially identical nucleic acids. Corre 
sponding amino acids may be the same amino acids or they 
may be differing amino acids sharing one or more charac 
teristics With respect to charge, polarity, acidity, hydrophi 
licity, hydrophobicity, or siZe. Preferably, the USP mutations 
disclosed in Table 1 are made in corresponding amino acids 
of RXR and other nuclear hormone receptors. 
For exemplary purposes, in human RXR, Cys432 and 
His435 on ot-helix 11 make contact With the distal end of the 
9-cis RA ligand at tWo methyl branches (C 16, C 17) and 
also at the terpene backbone (FIGS. 3A,B). The correspond 
ing tWo residues on ot-helix 11 of Drosophila USP (Cys472 
and His475) are highly conserved in other USPs Jones et al., 
Insect Biochem. Mol. Biol. 30, 671-679; and point into the 
ligand-binding pocket of USP crystal structures (FIG. 3C, 
Billas et al. (2000) J. Biol. Chem. 276, 7465-7474., Clayton 
et al. (2000) Proc. Natl. Acad. Sci. USA 98, 1549-1554). 
Other residues that contact 9-cis RA in hRXR are also 
conserved in identity and similar location in the ligand 
binding pocket of USP, such as Gln288, Trp318 and Leu3 67 
in USP corresponding to Gln275, Try305 and Leu326 of 
RXR, respectively (FIG. 3B-D). If an epoxy famesoid-like 
ligand Were to reside in the USP ligand-binding pocket along 
a similar trace as does 9-cis RA in RXR, then the terpene 
backbone and the methyl branches C 12 and C 15 at the 
distal end of the epoxy famesoid ligand might be similarly 
placed to interact With His475 and Cys472 in USP, as does 
9-cis RA interact With Cys432 and His435 in RXR (FIG. 
3B-D). 
USPs, Which compared to RXR are unusual for their 
stretch of additional amino acids inserted after ot-helix 5, 
have recently been cocrystaliZed With fortuitous phospho 
lipid pseudoligands Billas et al. (2000) J. Biol. Chem. 276, 
7465-7474., Clayton et al. (2000) Proc. Natl. Acad. Sci. USA 
98, 1549-1554. These cocrystals had a relatively large total 
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van der Waals volume of the USP ligand-binding pocket 
(:1300 A3), compared to the volume of JH III (259 A3 
Bogan, et al., (1998) Nat. Struct. Biol. 5, 679-681). HoW 
ever, the volume of the PPARY ligand-binding pocket (simi 
lar to that of USP, :1300 A3 Nolte et al. (1998) Nature 395, 
137-143) is also much larger than that of its natural ligand 
15-deoxy-Al2’l4-prostaglandin J 2 (Which has a volume simi 
lar to that of JH III, at 301 A3 Bogan, et al., (1998) Nat. 
Struct. Biol. 5, 679-681), yet this prostaglandin ligand is 
able to bind and transcriptionally activate the PPARY; 
KlieWer et al (1995) Cell 83, 813-819. In addition, the 
volume of [3-estradiol (Which at 245-251 A3 is smaller than 
methyl epoxyfarnesoate; Bogan, et al., (1998) Nat. Struct. 
Biol. 5, 679-681), is approximately half the volume of the 
ligand-binding pocket of the estrogen receptor (450-500 A3 ; 
BrZoZoWski, et al (1997) Nature 389, 753-758., Shiau, et al 
(1998) Cell 95, 927-937), Yet, [3-estradiol is nonetheless able 
to bind to and activate the estrogen receptor. Thus, PPARY 
and the estrogen receptor demonstrate that endogenous 
compounds much smaller than the total ligand-binding 
pocket volume of a nuclear hormone receptor can and do 
serve as natural activating ligands. The recently crystallized 
PXR, Which binds With, and is activated by, a variety of 
small and large ligands, also possesses a large 1300 A3 
ligand-binding pocket [Watkins et al., (2001) Science 292, 
2329-2333, and possesses an unusual additional stretch of 
amino acids that the authors postulated enables What Would 
otherWise be a smaller PXR ligand-binding pocket to 
enlarge to accommodate a large ligand. Important in these 
considerations is Whether there is a subregion in the ligand 
binding pocket in Which the local conformation corresponds 
Well to the conformation of a particular small ligand. 
Although the overall volume of the ligand-binding pocket 
observed in the cocrystals of USP (:1300 A3) is much larger 
than that of hRXRO. (:500 A3), the proximal subregion of 
the ligand-binding pocket of hRXR and USP are much more 
similar in volume and shape Clayton et al., (2000) Proc. 
Natl. Acad. Sci. USA 98, 1549-1554. The proximal subre 
gion of each of the tWo receptors also has a similar place 
ment of conserved amino acids that in hRXR interact With 
the terpenoid backbone of 9-cis RA (FIGS. 4A-D). In 
addition, 9-cis RA and methyl epoxyfarnesoate have similar 
van der Waals volumes of 291 and 258 A3, respectively 
Bogan, et al., (1998) Nat. Struct. Biol. 5, 679-681. These 
considerations suggest that methyl epoxyfamesoate-like 
metabolites cannot be dismissed a priori as potential USP 
agonists, merely on the basis of comparison of the volume 
of methyl epoxyfarnesoate vs. the reported total volume of 
the USP ligand-binding pocket. 
Given this disclosure exemplary corresponding amino 
acid positions in conjunction With standard protein align 
ment or 3-D modeling softWare common in the art, one of 
skill in the art Would readily be able to determine the 
location of other corresponding amino acids residues inside 
and outside the ligand binding pocket of USP, RXR and 
other nuclear hormone receptors. 
The term “nuclear hormone receptor response reporter 
construct” as used herein refers to a segment of DNA that 
comprises an operably linked nuclear hormone receptor 
response element, core promoter and reporter gene nucleic 
acid. These constructs are used to test Whether ligand 
binding of a nuclear hormone receptor causes the receptor to 
induce transcription of its target gene as assayed by expres 
sion of the reporter gene nucleic acid or by the activity of the 
reporter gene nucleic acid translational product. 
One embodiment of the nuclear hormone receptor 
response reporter construct has a an Aryl core (SEQ ID NO: 
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6) operably linked to a tWo copies of an EcRERF (SEQ ID 
NO: 7) nuclear hormone receptor response element. Prefer 
ably, other embodiments have a hormone receptor response 
element denoted by the formula YDRXZ having a direct 
repeat (DR) operably linked to a core promoter represented 
by SEQ ID NOs: 3, 4, 5, or 6. 
The term “operably linked” refers to the linkage of a DNA 
segment to another DNA segment in such a Way as to alloW 
the segments to function in their intended manners. A DNA 
sequence encoding a gene product is operably linked to a 
regulatory sequence When it is ligated to the regulatory 
sequence, such as, for example, promoters, enhancers and/or 
silencers, in a manner Which alloWs modulation of transcrip 
tion of the DNA sequence, directly or indirectly. For 
example, a DNA sequence is operably linked to a promoter 
When it is ligated to the promoter doWnstream With respect 
to the transcription initiation site of the promoter, in the 
correct reading frame With respect to the transcription ini 
tiation site and alloWs transcription elongation to proceed 
through the DNA sequence. An enhancer, such as the 
envisaged nuclear hormone receptor response element, is 
operably linked to a promoter and a DNA sequence coding 
for a gene product When they are ligated to the DNA 
sequence in such a manner as to increase or decrease, 
respectively, the transcription of the DNA sequence. 
Enhancers and silencers may be located upstream, doWn 
stream or embedded Within the coding regions of the DNA 
sequence. Linkage of DNA sequences to regulatory 
sequences is typically accomplished by ligation at suitable 
restriction sites or via adapters or linkers inserted in the 
sequence using restriction endonucleases knoWn to one of 
skill in the art. 
The term “nuclear hormone receptor response element” 
refers to a segment of DNA that is a target of ligand 
activated/homo- or heterodimeriZed nuclear hormone recep 
tor Which acts as an enhancer that When bound causes 
initiation of the formation of a transcriptional complex to 
being at the core promoter to Which the element is operably 
linked. In one embodiment, a hormone receptor response 
element is denoted by the formula YDRXZ comprising a 
direct repeat (DR) having tWo half sites separated by X 
nucleic acid bases; Wherein a forWard DR sequence is 
5'-AGGTCANxAGGTCA-3' (SEQ ID NO: 8) and a reverse 
DR sequence is 5'-TGACCTNxTGACCT-3' (SEQ ID NO: 
9); Wherein the element comprises at least one DR oriented 
in either a forWard or reverse orientation as indicated by Z 
(“f”:forWard, “r”:reverse); WhereinY equals 1 to 8 forWard 
and/ or reverse direct repeats; and X equals 1 to about 12. For 
example, the DRlf refers to “direct repeat l-forWard.” This 
means that there is a single forWard oriented DR sequence 
With tWo half-sites, With a single nucleotide space betWeen 
the tWo half-sites. As such, DRlf has the sequence AGGT 
CANAGGTCA (SEQ ID NO: 10), Wherein N is any base. 
The invention also envisages hormone response elements in 
various orientations. For example, 2DRllf might represent 
AGGTCANAGGTCAAGGTCANAGGTCA (SEQ ID NO: 
11; tWo adjacent DRs in the same orientation) and 2DRlfr 
AGGTCANAGGTCATGACCTNTGACCT (SEQ ID NO: 
12; tWo adjacent DRs in the opposite orientation as the ?rst 
example.) One of ordinary skill in the art could readily 
appreciate the potentially large number of variations and 
combinations envisaged. Preferably, the nuclear hormone 
receptor response element is a DRl, DR2, DR4, or DRl2 
response element With the proviso that envisaged receptor 
response element does not include a speci?c 4DRl2iffr 
element With a reverse oriented DRl2 preceded by three 
forWard oriented DRl2s. 
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An another embodiment, the nuclear hormone receptor 
response element comprises the hormone response element 
EcRE having the sequence 5; GAGGTCAATGACCTC-3' 
(SEQ ID NO: 7). 
The term “core promoter region” refers to a DNA 
sequence that acts as a site of initiation for the formation of 
a transcriptional complex that Will transcribe one or more 
nucleic acid sequences. It is located upstream With respect to 
the direction of transcription of the transcription initiation 
site of the gene, and is structurally identi?ed by the presence 
of a binding site for DNA-dependent RNA polymerase and 
transcription initiation sites. Mo st preferably, the promoter is 
doWn stream of and operably linked to the nuclear hormone 
response element. More preferably, the promoter is the 
BJHSPI core promoter, the JHE core promoter (SEQ ID 
NO: 22), BJHSP2Core (SEQ ID NO: 5), AJHSPlCore (SEQ 
ID NO: 3), BJHSPl (SEQ ID NO: 4) or the ArylCore (SEQ 
ID NO: 6). These core promoter sequences are described in 
Jones et al., (1995) Gene, 173: 209-214. 
The term “induction” refers to an increase in nucleic acid 
sequence transcription or expression brought about by 
nuclear hormone receptor response element binding of a 
ligand activated/homo- or heterodimeriZed nuclear hormone 
receptor relative to some basal level of transcription. Pref 
erably, hetero- or homodimeriZed ligand bound nuclear 
hormone receptor binds to a nuclear hormone receptor 
response element and induces transcription of a reporter 
gene as measured by construct activity. 
The term “construct activity” refers to the extent of 
expression of a nucleotide sequence that is operably linked 
to the nuclear hormone receptor response reporter construct 
Whose activity is being measured. Construct activity may be 
measured directly by determining the amount of RNA 
transcript produced, for example by Northern blot analysis 
or indirectly by determining the amount of product coded for 
by the linked nucleic acid sequence, such as a reporter 
nucleic acid sequence linked to the promoter. Alternatively, 
construct activity is measured as a function of the activity of 
a protein encoded by a reporter nucleic acid sequence 
operably linked to the receptor response element and core 
promoter. 
A “reporter nucleic acid sequence” is a DNA molecule 
that expresses a detectable gene product, Which may be RNA 
or protein. The detection may be accomplished by any 
method knoWn to one of skill in the art. For example, 
detection of mRNA expression may be accomplished by 
using Northern blot analysis and detection of protein may be 
accomplished by staining With antibodies speci?c to the 
protein, e.g. Western blot analysis. Preferred reporter nucleic 
acid sequences are those that are readily detectable. A 
reporter nucleic acid sequence may be operably linked in a 
DNA construct With a nuclear hormone receptor response 
element such that detection of the reporter nucleic acid 
sequence product provides a measure of the construct activ 
ity of the regulatory sequence. Examples of reporter nucleic 
acid sequences include, but are not limited to, those coding 
for alkaline phosphatase, chloramphenicol acetyl transferase 
(CAT), luciferase, beta-galactosidase and alkaline phos 
phatase. 
Construction of expression vectors containing the novel 
nuclear hormone receptor response reporter constructs, can 
be accomplished by methods knoWn to one of skill in the art. 
Typically nuclear hormone receptor response reporter con 
struct Will be cloned into an expression vector via suitable 
restriction endonuclease sites. The expression vector may be 
a plasmid, virus or a cosmid, for example. The cloned 
expression vector may then be transfected into the target 
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host cells and successfully transformed cells may be selected 
based on the presence of a suitable marker nucleic acid 
sequence as described above. 
DNA is commonly transferred or introduced into recipient 
mammal or insect cells by calcium phosphate-mediated gene 
transfer, electroporation, lipofection, viral infection and the 
like. General methods, vectors and general considerations 
for gene transfer and expression may be found in M. 
Kriegler, Gene Transfer and Expression: A Laboratory 
Manual, Stockton Press (1990). Direct gene transfer to cells 
in vivo is achieved by the use of modi?ed viral vectors, 
including retroviruses, adenoviruses, adeno-associated 
viruses and herpes viruses, liposomes, and direct injection of 
DNA into certain cell types. See, e.g., Wilson, Nature, 365: 
691-692 (1993); Plautz et al, Annals NY Acad. Sci., 716: 
144-153 (1994); Farhood et al, Annals NYAcad. Sci., 716: 
23-34 (1994) and Hyde et al Nature, 362: 250-255(1993). 
Furthermore, cells may be transformed ex vivo selected as 
described earlier and introduced directly at localized sites by 
injection, e.g., intra-articular, intracutaneous, intramuscular 
and the like. 
This invention includes substantially identical polynucle 
otides that hybridize under stringent conditions (as de?ned 
herein) to all or a portion of the invention’s mutant receptor 
sequences or hormone response element sequences (i.e., 
target sequences) or their complements. Under stringent 
hybridization conditions, only highly complementary, i.e., 
substantially similar nucleic acid sequences, hybridize. Pref 
erably, such conditions prevent hybridization of nucleic 
acids having 4 or more mismatches out of 20 contiguous 
nucleotides, more preferably 2 or more mismatches out of 20 
contiguous nucleotides, most preferably one or more mis 
match out of 20 contiguous nucleotides. The hybridizing 
portion of the hybridizing nucleic acid is at least about 80%, 
preferably at least about 95%, or most preferably about at 
least 98%, identical to the sequence of a portion or all of a 
target sequence, or its complement. 
Hybridization of a nucleic acid to a nucleic acid sample 
under stringent conditions is de?ned beloW. Nucleic acid 
duplex or hybrid stability is expressed as a melting tem 
perature (Tm), Which is the temperature at Which the probe 
dissociates from the target DNA. This melting temperature 
is used to de?ne the required stringency conditions. If 
sequences are to be identi?ed that are substantially identical 
to the probe, rather than identical, then it is useful to ?rst 
establish the loWest temperature at Which only homologous 
hybridization occurs With a particular concentration of salt 
(eg SSC or SSPE). Then assuming that 1% mismatching 
results in a 1° C. decrease in Tm, the temperature of the ?nal 
Wash in the hybridization reaction is reduced accordingly 
(for example, if sequences having >95% identity With the 
probe are sought, the ?nal Wash temperature is decrease by 
50 C.). In practice, the change in Tm can be between 05° C. 
and 15° C. per 1% mismatch. 
Stringent conditions involve hybridizing at 68° C. in 
5><SSC/5>< Denhart’s solution/ 1.0% SDS, and Washing in 
0.2><SSC/0.1% SDS at room temperature. Moderately strin 
gent conditions include Washing in 3><SSC at 42° C. The 
parameters of salt concentration and temperature be varied 
to achieve optimal level of identity betWeen the primer and 
the target nucleic acid. Additional guidance regarding such 
conditions is readily available in the art, for example, 
Sambrook, Fischer and Maniatis, Molecular Cloning, a 
laboratory manual, (2nd ed.), Cold Spring Harbor Labora 
tory Press, NeW York, (1989) and F. M. Ausubel et al eds., 
Current Protocols in Molecular Biology, John Wiley and 
Sons (1994). 
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The invention provides a set of biochemical and cellular 
tools and assays that enable the user to identify to chemical 
compounds that are effective in activating or blocking 
particular hormone-dependent regulatory pathWays in vari 
ous organisms. 
The invention relates to mutant nuclear hormone recep 
tors that encode mutant nuclear hormone receptors, in Which 
particular amino acid residues are substituted With respect to 
Wild type, so as to be able to detect ligand binding to the 
mutant receptor by either a change in a physical property of 
the mutant receptor and/or an transcriptional induction of a 
nuclear hormone receptor construct. These proteins bind and 
interact With ligands in substantially the same Way as their 
Wild type counter part. HoWever, certain amino acid substi 
tutions readily alloW changes in protein ?uorescence With 
respect to Wild type facilitating the detection betWeen ligand 
and receptor. 
Another aspect of the invention relates to a method 
identifying ligands of nuclear hormone receptors compris 
ing: contacting a mutant nuclear hormone receptor protein 
With a candidate ligand; and determining Whether there is a 
change in a physical property of the protein or a change in 
the transcriptional activity of the protein. Preferably, such a 
method is scaled up and carried out by an apparatus capable 
of simultaneously screening libraries of small molecules 
generated by combinatorial chemistry or similar techniques 
typical in the art. 
Another aspect of the invention relates to a nucleic acids 
that encode dominant negative mutant nuclear hormone 
receptors. Preferably, dominant negative mutants are used to 
interfere With endogenous nuclear hormone signaling path 
Ways. Although the skilled artisan could envisage a multi 
tude of uses, preferably, such mutants are used in combina 
tion With nuclear hormone receptor reporter construct to 
control that a candidate ligand is binding an endogenous 
nuclear hormone receptor and that this binding is the result 
of in induction of the nuclear hormone receptor reporter 
construct rather than some unforeseen independent mecha 
nism. 
Another aspect of the invention relates to a nuclear 
hormone receptor response element denoted by the formula 
YDRXZ comprising a direct repeat (DR) comprising tWo 
half sites separated by X nucleic acid bases; Wherein Z 
indicates a forWard DR sequence of 5'-AGGTCA(N),CAG 
GTCA-3' (SEQ ID NO: 8) and/or a reverse DR sequence of 
5'-TGACCT(N)xTGACCT-3' (SEQ ID NO: 9); Wherein the 
element comprises at least one DR oriented in either a 
forWard or reverse orientation; Wherein Y equals 1 to 8 
forWard and/or reverse direct repeats; and X equals 1 to 
about 12. Such elements may be operably linked to a Wide 
variety of core or basal promoters to test nuclear hormone 
receptor activation. 
Another aspect of the invention relates to nuclear hor 
mone receptor reporter construct comprising a nuclear hor 
mone receptor response element, a promoter and a reporter 
nucleic acid sequence operably linked to one another; 
Wherein the hormone receptor response element denoted by 
the formula YDRXZ comprises a direct repeat (DR) com 
prising tWo half sites separated by X nucleic acid bases; 
Wherein Z connotes a forWard DR sequence of 5'-AGGTCA 
(N)xAGGTCA-3' (SEQ ID NO: 8) and/or a reverse DR 
sequence of 5'-TGACCT(N)xTGACCT-3' (SEQ ID NO: 9); 
Wherein the element comprises at least one DR oriented in 
either a forWard or reverse orientation; Wherein Y equals 1 
to 8 forWard and/or reverse direct repeats; and X equals 1 to 
about 12; and Wherein the promoter is selected from the 
group consisting of SEQ NOs: 3, 4, 5, and 6. 
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In another aspect of the invention, the set of tools and 
assays disclosed herein are useful for screening for com 
mercial compounds that Will have particular e?fects on the 
function of USP/RXR receptors Will lead to the identi?ca 
tion of environmentally safe, neW insecticides that are 
speci?c for disrupting the hormone receptor-dependent 
physiological regulation of insects (pests of food/?ber/ 
ornamental plants, or vectors of disease agents) but not 
disrupt the hormone receptor-dependent physiological regu 
lations of humans or other non-target vertebrates. These 
assays could be designed in a ‘scaled up’ format, in Which 
thousands of test chemicals are e?fectively assays for par 
ticular e?fects to disrupt the hormone receptor-dependent 
regulation of insects. 
EXAMPLE 1 
Cell Culture and Transfections 
Spodoplera?’ugiperda cell line, Sf9, Was maintained and 
transfected as described previously Jones et al (1998) Bio 
chem. J. 335, 79-84; Jones et al. (2000) Biochem. J. 346, 
233-240. As an internal control to compare activities of 
different constructs, 0.3 pg of a constituitive heat-shock 
promoter-driven [3-galactosidase gene Was cotransfected. To 
study the role of USP in activation of the nuclear hormone 
receptor response element fused to core promoter in methyl 
epoxyfamesoate-treated cells, cloned D. melangasler USP 
(dUSP) cDNA and its derivatives containing mutations in 
the ligand-binding pocket Were cotransfected With the 
reporter and internal control plasmids. At 36 h after the 
transfection, the cells Were treated With 75 um methyl 
epoxyfamesoate (Sigma) in ethanol carrier (1% ?nal ethanol 
concentration) or just ethanol carrier only (previous studies 
demonstrated methyl epoxyfamesoate e?fects Were dose 
dependent, With maximum near 75 pm). After 48 h of the 
treatment, the cells Were harvested and the activity of the 
luciferase reporter Was measured using a luciferase assay kit 
(Promega) in a multipurpose scintillation counter (Beckman, 
Fullerton, Calif.). [3-Galactosidase activity Was measured 
using chlorophenol red-0t-d-galactopyranoside monosodium 
(CPRG; Roche Molecular Biochemicals) as a colorimetric 
substrate. 
EXAMPLE 2 
Nuclear Hormone Receptor Response Elements 
The sequences and characteristics of the core promoter 
(61 to +28) of the JHE gene Were described by Jones et al. 
(2001) Insect Biochem. Mol. Biol. 32, 33-49; Jones et al 
(1998) Biochem. J. 335, 79-84; 79-84; Jones et al. (2000) 
Biochem. J. 346, 233-240. The core promoter responds to 
respond to methyl epoxyfamesoate through a heterologous 
5' ?anking direct repeat motif in cell transfection assay. This 
Core promoter reporter Was cloned into KpnI/BglII sites of 
pGL3. An NheI site Was then placed immediately 5' to the 
KpnI site, and multiple direct repeat (DR) sequences Were 
cloned into the NheI site by the folloWing method. Comple 
mentary oligonucleotides encoding the particular DR motif 
Were synthesiZed, With each oligonucleotide possessing at 
its 5' end a four base overhang of an NheI restriction site 
(CTAG). Upon annealing, the double stranded oligonucle 
otides Would then have a CTAG overhang at each 5' end. The 
annealed oligonucleotides Were then ligated into concatam 
ers, fractionated by native PAGE and the gel fractions 
corresponding to higher concatamer forms recovered and 
ligated into the NheI site. Speci?c DR sequences for the 
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oligonucleotides Were (upper strand) for DR1: 5'-CAAG 
GTCAAAGGTCAG-3' (SEQ ID NO: 13), for DR4: 
5'-CAAGGTCAAGAAAGGTCAG-3' (SEQ ID NO: 14), 
for DR12: 5'-CAAGGTCAAGAAGGCCAAAGAGGT 
CAG-3' (SEQ ID NO: 15; CTAG on 5' ends not shoWn). The 
recovered YDRXCore constructs (X representing 1, 4 or 12 
intervening bases; Y representing the number of tandem 
pairs of direct repeats) Were veri?ed by sequencing. The 
intervening sequences in the DR1 and DR4 motifs Were 
randomly chosen, While the DR12 sequence used is found in 
the ecdysteroid-sensitive ng-1 and ng-2 genes that are 
expressed during metamorphosis of D. melanogasler, and 
can serve in vitro as a binding site for the various receptor 
dimers involving USP (ecdysteroid receptor (EcR)/USP 
heterodimer, USP/DHR38 heterodimer and USP/USP 
homodimer. 
Placement of four tandem copies of a DR12 motif 
(CAAGGTCANNNNNNNNNNNNAGGTCAG SEQ ID 
NO: 16), FIG. 1A) at 5' to the Core promoter reporter 
(4DR12Core construct, FIG. 1B) yielded a 10-fold induction 
in promoter activity in response to treatment of the trans 
fected Sf9 cells With methyl epoxyfarnesoate (FIG. 1B). In 
contrast, insertion of a cassette containing four tandem 
copies of either a DR1 or DR4 motif yielded only a 2.5- and 
3.5-fold induction, respectively (FIG. 1B). This dilferential 
result con?rms that the 10-fold activation observed With the 
4DR12Core construct Was caused by the sequence of the 
inserted DR12 cassette itself, and Was not due to either 
insertional disruption or creation of a putative cryptic regu 
latory element at the vector multiple cloning site. Due to the 
highest reporter activity being obtained With the DR12 
motif, We focussed on the DR12 repeat construct, toWards 
the goal of the study of ligand activation of USP. 
We then con?rmed that sequences in the AGGTCA half 
sites themselves of the DR12 motif Were necessary for 
transducing the methyl epoxyfarnesoate signalling. We took 
advantage of the previous report that mutation of each half 
site abrogated the ability of DR12 motif to enhance ecdys 
teroid transcriptional activation D’Avino et al. (1995) Mol. 
Cell. Endo. 113, 1-9. When We mutated here each half site 
of the DR12 motif (in a construct containing a single DR12 
in order to simplify mutational analysis; 1DR12mutCore), 
the responsiveness of the 1DR12mutCore to methyl epoxy 
famesoate Was no greater than the background of a Core 
promoter With no enhancer (FIG. 2B); in contrast to the 
responsiveness of the Core promoter in the presence of a 
Wild-type DR12 (1DR12Core, FIG. 2B). 
EXAMPLE 3 
Nuclear Extracts and Electrophoretic Mobility Shift Assay 
Nuclear extracts Were isolated from Sf9 cells as previ 
ously described Jones et al. (2001) Insect Biochem. Mol. 
Biol. 32, 33-49; Jones et al (1998) Biochem. J. 335, 79-84; 
79-84; Jones et al. (2000) Biochem. J. 346, 233-240. For the 
DR12 probe, the double stranded DR12 oligonucleotide 
(sequence as shoWn above) Was 5' end-labelled With 32P by 
T4 polynucleotide kinase (NeW England Biolabs Inc.), and 
then puri?ed from a 20% native polyacrylamide gel. The 
same double stranded DR12 oligonucleotide Was used in 
100-fold excess as a self competitor. For the 4DR12Core 
probe, the 4DR12Core sequence Was liberated from the 
vector as a 148-bp ClaI/HindIII fragment, and Was 5' end 
labelled With 32P and puri?ed. The same, unlabelled frag 
ment Was used at 100-fold excess as a self competitor. As a 
negative control for speci?city in gel shifts, the 36 bp 
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BglII/KpnI polylinker region fragment of the pGL3 vector 
Was liberated and recovered from loW melting point agarose 
gels and used as a 100 nonself competitor (sequence: 
GGTACCGAGCTCTTACGCGTGCTAGC 
CCGGGCTCGA, SEQ ID NO: 17). Either a ?nal concen 
tration of 500 nm of His-tagged Wild-type USP or His 
tagged mutant Cys472Ala/His475Leu (=C472A/H475L), 
or ?ve micrograms of nuclear proteins, Were incubated With 
the given probe on ice for 30 min in binding buffer (10 mM 
Tris/HCl, pH 7.5; 50 mM NaCl, 0.5 mM EDTA, 5% 
glycerol, 1 mM MgCl2, and 1 mM dithiothreitol). In some 
experiments, nuclear proteins Were preincubated With the 
probe for 30 min folloWed by incubation With anti-USP mAb 
(a gift from F. Kafatos, EMBL, Heidelberg), or monoclonal 
Elav antibody (Developmental Studies Hybridoma Bank, 
University of IoWa), for an additional 1 h on ice. Samples 
Were then subjected to 4% (W/v) polyacrylamide gel elec 
trophoresis in 0.5 Tris/borate/EDTA buffer. After electro 
phoresis, the gels Were dried and exposed to Kodak ?lm at 
70° C. for 12-48 h. 
As an independent con?rmation of the important role of 
the tWo direct repeat half sites in the DR12 motif, We 
demonstrated that in a gel mobility shift assay With Sf9 
nuclear extracts, the DR12 motif probe yielded a shifted 
probe band that could be competed With excess, unlabelled 
Wild-type DR12. HoWever, the same DR12 mutated in its 
tWo half sites that had failed to support methyl epoxyfarne 
soate-enhanced transcription in the cell transfection assay 
also correspondingly failed to compete With the Wild-type 
DR12 probe in the gel shift assay (FIG. 2A), con?rming the 
functional necessity of the tWo half sites for interaction With 
a nuclear component(s). Thus, the lack of binding to the 
mutant DR12 combined With the lack of a transcriptional 
effect of that same mutant DR12 indicates that the speci?c 
binding to the Wild-type DR12 observed here relates to its 
positive action to transduce the methyl epoxyfamesoate 
signalling observed in the transfection assay. The gel mobil 
ity shift assay using Sf9 nuclear extracts detected a single 
major complex binding to the DR12 probe (FIG. 2C). An 
anti-dUSP mAb (AB11, epitope on DNA binding domain) 
displaced the endogenous USP in the major complex binding 
to the DR12 probe (FIG. 2C). The speci?city of the AB11 
monoclonal antibody effect on USP binding Was further 
con?rmed in that no such effect Was produced by a negative 
control monoclonal antibody against the transcription factor 
Elav. 
EXAMPLE 4 
USP Mutants 
Point mutations in the ligand-binding domain of dUSP 
Were made With a ChameleonTM double-stranded site-di 
rected mutagenesis kit (Stratagene) according to the manu 
facturer’s instructions. The selection primer used to change 
the unique NdeI (underlined) site in the pIE1-4 vector Was 
CGGTATTTCACACCG 
CAcATGGTGCACTCTCAGTACAATC (SEQ ID NO: 18). 
The primer to mutate Q288 to alanine in the ligand-binding 
pocket Was: GTGCCAAGTGGTCAACAAA 
g?CTCTTCCAGATGGTCGAATAC (SEQ ID NO: 19). A 
primer that targeted tWo amino acids Was used to make the 
double mutation in C473A and H476L because of their 
adjacent locations, With the sequence: GCGATCGAT 
CAGCCTGAAGgQCAGGAT 
@CTGTTCCTCTTCCGCATTAC (SEQ ID NO: 20). A 
primer that replaced tWo proline residues (P498, P499) at the 
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end of ot-helix 12 With tryptophan residues 
5'-CTTTCTCGAGCAGCTGGAGGCGtgG 
tgGCCACCCGGCCTGGCGATGAAACT-3' (SEQ ID NO: 
21). All mutant constructs Were con?rmed by DNA sequenc 
1ng. 
For expressing dUSP in Sf9 cells, PCR-generated full 
length Wild-type and point-mutated dUSP coding sequences 
Were cloned into PmeI and NotI sites of the pIE1-4 vector 
(Novagen) and con?rmed by sequencing, and for bacterial 
overexpression Were cloned into pET32EK (Novagen). 
WaSZ 
EXAMPLE 5 
Extraction of Total Proteins and Immunoblotting Analysis 
Total Sf9 cell protein extracts from transfected Sf9 cells 
Were fractionated by SDS/PAGE, 8% (W/v) polyacrylamide 
gel, and then transferred onto a nitrocellulose membrane. 
USP Was detected using a primary USP AB11 monoclonal 
antibody and With an anti-mouse IgG-AP secondary Ig 
(Bio-Rad) by a BCIP/NBT color development solution 
(Bio-Rad). The USP signals Were normalized by an internal 
control, [3-actin, Which Was detected by a primary polyclonal 
[3-actin antibody (Sigma) and With an anti-rabbit IgG-AP 
secondary Ig (Southern Biotechnology Associates, Inc.). 
EXAMPLE 6 
Puri?cation of the His-USP Fusion Protein and Ligand 
binding Assay 
The homodimer-enriched fraction of bacterial recombi 
nant His-dUSP fusion protein Was puri?ed by nickel resin 
selection, elution With imidaZole, centrifugal concentration, 
and then gel permeation chromatography (Superdex 200) 
With procedures and chemical sources exactly as already 
described previously Jones et al. (2000) Insect Biochem. 
Mol. Biol. 30, 671-679. The homodimer-enriched fraction of 
the puri?ed His-USP fusion protein Was raised to 2 ml of 
NaCl and a ?nal concentration of 0.5 pm. For a ?uores 
cence-based ligand-binding assay based on intrinsic tryp 
tophan ?uorescence Jones et al. (2001) Insect Biochem. 
Mol. Biol. 32, 33-49; Jones et al (1998) Biochem. J. 335, 
79-84; 79-84; Jones et al. (2000) Biochem. J. 346, 233-240; 
Jones et al (1997) Proc. Natl. Acad. Sci. USA 94, 13499 
13503, ligand or ethanol carrier Was added and the receptor 
preparation excited at 290 nm and monitored for emission at 
340 nm, until the signal from the receptor had stabiliZed. 
Fluorescence Was measured three times for each sample, 
With standard deviation typically smaller than the graphical 
plotted datum point. Each ?uorescence experiment Was 
replicated on three or more independent occasions, each 
time With similar results. 
His-tagged dUSP dominant negative double mutant 
Cys472Ala/His475Leu (C472A/H475L) Was over expressed 
in methyl epoxyfamesoate-treated Sf9 cells that Were 
cotransfected With the 4DR12Core reporter plasmid. Cells 
transfected With either empty pIE1-4 vector, or that vector 
expressing Wild-type dUSP, responded to methyl epoxyfar 
nesoate application With a similar induction of the 
4DR12Core promoter (FIG. 4A). HoWever, cells transfected 
With the plasmid expressing the C472A/H475L mutant 
exhibited a distinct suppression in the level of methyl 
epoxyfarnesoate-induced activation, as compared With the 
activation observed for cells transfected With either the 
empty plasmid or plasmid expressing Wild-type dUSP (FIG. 
4A). In addition, cotransfection of the empty vector, or 
vector expressing either Wild-type dUSP or the C472A/ 
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H475L mutant, did not affect the basal activation exhibited 
When the Core promoter Without DR12 motifs Was used. 
Together, these data demonstrate that the suppression in 
methyl epoxyfarnesoate-induced activation caused by over 
expression of the C472A/H475L double mutant Was not due 
to nonspeci?c titration of coactivators required by a receptor 
other than USP and not due to disruption of Core-binding 
basal transcription components independent of action 
through the DR12 enhancer. In addition, overexpression of 
either the C472A/H475L double mutant or the Wild-type 
dUSP did not change the level of endogenous USP (FIG. 
4A), con?rming that overexpression of exogenous dUSP did 
not indirectly a?fect the methyl epoxyfamesoate-activation 
pathWay by disruption of endogenous USP expression. 
Under the model that overexpression of the C472A/ 
H475L double mutant competed With endogenous USP in 
the pathWays for transduction of the exogenous methyl 
epoxyfamesoate signal, the level of e?fect of the double 
mutant ought to be dependent on its dose. Indeed, a pro 
gressive increase in the intracellular concentration of this 
double mutant (With endogenous USP level remaining 
unchanged) caused progressive suppression in the methyl 
epoxyfamesoate-activation of the DRl2Core promoter, 
doWn to the transcriptional level observed for the Core 
promoter Without DR12 enhancers (FIG. 4B). Over the 
range of the progressive suppression of the methyl epoxy 
farnesoate-activated transcription there Was no e?fect of the 
double mutant on the basal level of transcription in EtOH 
treated controls. This background of the blocked activation 
pathWay Was used to test Whether activation by methyl 
epoxyfamesoate treatment Was actually dependent on the 
presence of Wild-type USP. As shoWn in FIG. 4C, the 
activation of the 4DRl2Core promoter in methyl epoxyfar 
nesoate-treated cells Was monotonically restored in a man 
ner dependent on the increasing dose of the added Wild-type 
dUSP. Again, over the range of the monotonic restoration of 
methyl epoxyfarnesoate-activated transcription, there Was 
no e?fect of the transfected Wild-type dUSP on the basal level 
of transcription in EtOH-treated controls. 
The ability of the C472A/H475L mutant to bind DNA and 
to homodimeriZe to con?rm Was examined that the muta 
tions to the ligand-binding pocket did not generally deform 
receptor structure. As shoWn in FIG. 5A, under electro 
phoretic mobility shift assay conditions, both the Wild-type 
dUSP and the C472A/H475L mutant dUSP similarly bound 
to a DR12 motif. In addition, both receptor preparations 
bound to the probe similarly in part as monomer and in part 
as homodimer. The homodimeriZation of RXR and other 
steroid receptor superfamily members is primarily due to 
contacts in the ligand-binding domain that are outside of the 
ligand-binding pocket (in addition to some contacts also in 
the DNA-binding domain). The similar DNA binding and 
homodimeriZation capacities of the Wild-type dUSP and 
mutant C472A/H475L dUSP is strongly indicative that the 
DNA-binding domain, and the parts of the ligand-binding 
domain that are outside of the ligand-binding pocket, are in 
a functionally similar conformation for both the Wild-type 
and mutant receptors. Thus, any di?ference detected in 
ligand binding of the tWo receptors is most reasonably 
inferred as arising from di?erences in the architecture inside 
the cavity of the ligand-binding pocket due to the C472A/ 
H475L point mutations. 
EXAMPLE 7 
The ability of the Wild-type dUSP and dominant negative, 
ligand-binding pocket mutant dUSP to bind methyl epoxy 
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famesoate Was tested. In a ligand-binding assay that detects 
methyl epoxyfamesoate binding through its e?fects to sup 
press intrinsic ?uorescence of dUSP, Jones et al., (1998) 
Biochem. J. 335, 79-84., Jones et al. (1997) Proc. Natl. 
Acad. Sci. USA 94, 13499-13503, the bacterially overex 
pressed His-tagged Wild-type dUSP indeed exhibited sup 
pressed the ?uorescence due to the binding of methyl 
epoxyfarnesoate (FIG. 5B). HoWever, the C472A/H475L 
mutant dUSP did not exhibit a signi?cant response to 
epoxymethyl farnsoate (FIG. 5B). This result Was repro 
duced With independent preparations of the Wild-type dUSP 
and C472/H475L dUSP. These results indicate that C472A/ 
H475L behaves as a dominant negative mutant in the 
pathWay for methyl epoxyfamesoate activation of the 
4DRl2Core promoter and that the activity is due to the e?fect 
of the C472A/H475L mutations on the ligand-binding activ 
ity of USP. 
EXAMPLE 8 
USP Mutants With Altered Fluorescence 
Some models of nuclear hormone receptor action postu 
late that binding of ligand to the ligand-binding pocket 
induces a tertiary conformational change involving the 
movement of ot-helix 12 to a neW position, SteinmetZ et al 
(2001) Annu. Rev. Biophys. Biomol. Struct. 30, 329-359. 
HoWever, the tWo published crystal structures of USP in 
complex With a phospholipid located at the opening of the 
ligand-binding pocket shoW ot-helix 12 in a position that the 
investigators described as so ?rmly ‘locked’ against other 
residues of the ligand-binding domain that ot-helix 12 Would 
not be able to move even if the phospholipid Were not 
present Billas et al. (2000) J. Biol. Chem. 276, 7465-7474; 
Jones et al (1997) Proc. Natl. Acad. Sci. USA 94, 13499 
13503. Therefore, the hypothesis that ot-helix 12 is so ?rmly 
locked in position that it does not move, by replacing tWo of 
the four continuous proline residues at the end of ot-helix 12 
With tryptophan residues, Was tested. Under the model that 
USP ot-helix 12 does not move upon binding of methyl 
epoxyfarnesoate in the ligand-binding pocket, these tWo 
tryptophan residues Would only raise the constant back 
ground intrinsic ?uorescence of the receptor, but, on account 
of the fact that they (as part of the ?xed ot-helix 12) do not 
move in position, their level of ?uorescence Would not 
change upon binding of methyl epoxyfamesoate into the 
pocket. Therefore, their constant background ?uorescence 
Would not enhance or disguise the suppression in ?uores 
cence exhibited by the tWo other natural tryptophan residues 
(on ot-helix 5) upon binding of methyl epoxyfarnesoate. 
Alternatively, if ot-helix 12 does move in position upon 
binding of methyl epoxyfamesoate, then the change in the 
local environment of the tWo added tryptophan residues on 
ot-helix 12 may change their ?uorescence in a Way that 
yields a markedly di?ferent overall ?uorescence pattern for 
the receptor. Indeed, as FIG. 6B shoWs, in this test the 
Wild-type USP With only tWo natural tryptophan resides on 
ot-helix 5 exhibits a distinct suppression in ?uorescence 
upon binding of methyl epoxyfarnesoate. In contrast, the 
mutant USP containing tWo additional tryptophan residues 
at the end of -helix 12 shoWed a much di?ferent pro?le, 
instead sharply increasing in ?uorescence before then 
decreasing (Panel C). Collectively, these markedly di?ferent 
patterns of ?uorescent response are most easily explained by 
a model in Which -helix 12 does move in relative position, 
upon the binding of methyl epoxyfarnesoate into the ligand 
binding pocket of USP. 








